Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axogen, Inc.AXGN · Entity 4297 | Chief Innovation Officer | March 16, 2026 | March 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axogen, Inc.
Report date March 16, 2026 · Filed March 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 262,781 |
Ending reported balance
After 2026-03-16 transaction · row 4
4 source rows · reconciled sequenceRow 1 · 2026-03-16 · Exercise / conversion · Acquired 6,363 · Balance 259,297 F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Row 2 · 2026-03-16 · Tax withholding · Disposed 2,870 · Balance 256,427 F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. Row 3 · 2026-03-16 · Exercise / conversion · Acquired 11,575 · Balance 268,002 F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Row 4 · 2026-03-16 · Sale · Disposed 5,221 · Balance 262,781 F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 6,363 |
Reported balance
After 2026-03-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-03-16 · Exercise / conversion · Acquired 6,363 · Balance 6,363 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 11,575 |
Reported balance
After 2026-03-16 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-03-16 · Exercise / conversion · Acquired 11,575 · Balance 11,575 F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026.
F2: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale.
F3: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.
F4: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates.
F5: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 11,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · derivative · entry 6 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,575 Underlying: Common Stock · 11,575 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,363 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · derivative · entry 5 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,363 Underlying: Common Stock · 6,363 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units are fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vested each 12 months thereafter. Vested shares are delivered to the reporting person upon the vesting dates. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 5,221 | $32.84 | $171,457.64 |
DisclosureSEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · nonDerivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 262,781 F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 11,575 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 268,002 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 2,870 | $32.84 | $94,250.80 |
DisclosureSEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 256,427 F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the RSUs and does not represent an open market sale. Read SEC document |
| March 16, 2026 Filed Mar 18, 2026 20:11 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,363 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000048 · wk-form4_1773864674.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 259,297 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units ("RSUs") that vested on March 16, 2026. Read SEC document |
| March 01, 2026 Filed Mar 2, 2026 23:16 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 11,276 | $30.65 | $345,609.40 |
DisclosureSEC source: 0000805928-26-000043 · wk-form4_1772493371.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 252,934 F3 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of restricted stock units ("RSUs"). Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 23:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000043 · wk-form4_1772493371.xml · derivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,000 Underlying: Common Stock · 23,000 shares Expires not disclosed F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 23:16 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 10,702 | $31.90 | $341,393.80 |
DisclosureSEC source: 0000805928-26-000043 · wk-form4_1772493371.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 264,210 F2 · shares: No shares were sold by the reporting person. The transaction disclosed represents shares of the issuer's Common Stock withheld by the issuer in payment of the withholding tax liability incurred upon the vesting of performance stock units ("PSUs"). Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 23:16 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 33,780 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-26-000043 · wk-form4_1772493371.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 274,912 F1 · shares: This reflects the number of shares that became vested as of February 26, 2026, upon the attainment and certification of certain performance criteria. Read SEC document |
| December 09, 2025 Filed Dec 10, 2025 22:20 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 19,517 | $31.21 | $609,086.54 |
DisclosureSEC source: 0000805928-25-000165 · wk-form4_1765405224.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 241,132 F1 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units on December 4, 2025. This sale does not represent a discretionary trade by the Reporting Person. F2 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on December 9, 2025, in multiple transactions at $31.208 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| December 04, 2025 Filed Dec 5, 2025 21:55 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 40,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000150 · wk-form4_1764971712.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 260,649 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| September 16, 2025 Filed Sep 16, 2025 21:22 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 1,137 | $16.29 | $18,521.73 |
DisclosureSEC source: 0000805928-25-000116 · wk-form4_1758057719.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 220,649 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on September 13, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 13, 2025 Filed Sep 16, 2025 21:22 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000116 · wk-form4_1758057719.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 221,786 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| March 25, 2025 Filed Mar 26, 2025 20:52 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 38,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000048 · wk-form4_1743022368.xml · derivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,000 Underlying: Common Stock · 38,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F2 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F2 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 19, 2025 Filed Mar 19, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 15,111 | $17.50 | $264,442.50 |
DisclosureSEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · nonDerivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 217,762 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units on March 16, 2025. This sale does not represent a discretionary trade by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on March 19, 2025 in multiple transactions at $17.50 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 23,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · derivative · entry 7 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,150 Underlying: Common Stock · 23,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F7 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F7 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 6,362 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · derivative · entry 6 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,363 Underlying: Common Stock · 6,362 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · derivative · entry 5 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 23,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 232,873 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2025. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 6,362 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,723 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2025. Read SEC document |
| March 16, 2025 Filed Mar 19, 2025 21:24 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000041 · wk-form4_1742419444.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 203,361 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2025. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 00:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 8,296 | $18.35 | $152,231.60 |
DisclosureSEC source: 0000805928-25-000028 · wk-form4_1741134151.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 201,005 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on February 28, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on March 4, 2025 in multiple transactions at prices ranging from $18.34 to $18.72 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 28, 2025 Filed Mar 5, 2025 00:22 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 24,799 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000028 · wk-form4_1741134151.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 209,301 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| February 25, 2025 Filed Feb 26, 2025 21:23 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 972 | $16.50 | $16,038.00 |
DisclosureSEC source: 0000805928-25-000018 · wk-form4_1740604988.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,502 F2 · shares: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of performance stock units ("PSUs") on February 22, 2025. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person. F3 · price: The reported price in Column 4 is a weighted average sale price. These shares were sold on February 25, 2025 in multiple transactions at prices ranging from $16.42 to $17.47 per share. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Read SEC document |
| February 22, 2025 Filed Feb 26, 2025 21:23 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-25-000018 · wk-form4_1740604988.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,474 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| September 13, 2024 Filed Sep 13, 2024 20:30 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 2,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000129 · wk-form4_1726259429.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,974 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 3,141 | $7.68 | $24,122.88 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 6 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 177,474 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 721 | $7.68 | $5,537.28 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 167,890 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 21, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | SaleCommon Stock | 716 | $7.68 | $5,498.88 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 165,661 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 12,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · derivative · entry 9 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,725 Underlying: Common Stock · 12,725 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F6 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F6 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2026 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2024 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · derivative · entry 8 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,950 Underlying: Common Stock · 2,950 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · derivative · entry 7 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 12,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 5 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 180,615 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 2,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 168,611 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024. Read SEC document |
| March 16, 2024 Filed Mar 26, 2024 01:40 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-24-000049 · wk-form4_1711417219.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 166,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2024. Read SEC document |
| March 01, 2024 Filed Mar 5, 2024 21:33 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 50,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000805928-24-000031 · wk-form4_1709674382.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · Chief Innovation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 163,377 F1 · price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. Read SEC document |
| February 22, 2024 Filed Feb 23, 2024 21:02 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantPerformance Stock Units · Derivative | 68,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-003889 · doc4.xml · derivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,600 Underlying: Common Stock · 68,600 shares Expires not disclosed F1 · derivative.exercise_price: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number. F1 · derivative.exercise_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number. F1 · derivative.expiration_date: Represents the performance stock units ("PSUs") granted to the reporting person pursuant to the Issuer's Amended and Restated 2019 Long-Term Incentive Plan ("Plan") in respect of calendar year 2024. Each PSU represents the right to receive one share of Common Stock. PSUs will be eligible to be earned by the reporting person based on achievement with respect to an annualized absolute total shareholder return performance goal over a three-year performance period beginning February 22, 2024 and ending February 22, 2027, subject to the reporting person's continuous service through the end of such performance period. The number of PSUs indicated reflects the "target" number of PSUs granted to the reporting person and subject to availability under the Plan, the number of PSUs earned could range from 0% to 200% of such target number. Read SEC document |
| October 13, 2023 Filed Oct 14, 2023 00:29 UTC | Axogen, Inc. AXGN · Entity 4297 | Disposition to issuerCommon Stock | 864 | $4.04 | $3,490.56 |
DisclosureSEC source: 0000805928-23-000140 · wk-form4_1697243379.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,377 F2 · shares: This represents the number of shares of Common Stock that have been withheld by the issuer to satisfy tax withholding and remittance obligations in connection with the net settlement of the PSUs and does not represent an open market sale. Read SEC document |
| July 18, 2023 Filed Oct 14, 2023 00:29 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantCommon Stock | 1,579 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000140 · wk-form4_1697243379.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,241 F1 · shares: This reflects the number of shares issued upon the attainment of certain performance criteria. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:08 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantRestricted Stock Units · Derivative | 46,300 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000030 · wf-form4_167936091488272.xml · derivative · entry 8 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,300 Underlying: Common Stock · 46,300 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F7 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. F7 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregateshares vest on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:08 UTC | Axogen, Inc. AXGN · Entity 4297 | GrantEmployee Stock Option (right to purchase) · Derivative | 64,000 | $0.00 Strike: $8.27 | $0.00 |
DisclosureSEC source: 0000805928-23-000030 · wf-form4_167936091488272.xml · derivative · entry 7 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 64,000 Underlying: Common Stock · 64,000 shares Expires 2023-03-16 F6 · derivative.exercise_date: All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vest each 6 months thereafter. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000030 · wf-form4_167936091488272.xml · derivative · entry 6 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,000 Underlying: Common Stock · 3,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F5 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. F5 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2024 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2022, 25% of the aggregate shares vest on March 16, 2023, and 25% of the aggregate shares vest on March 16, 2024. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionRestricted Stock Units · Derivative | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000030 · wf-form4_167936091488272.xml · derivative · entry 5 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,900 Underlying: Common Stock · 5,900 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock. F4 · derivative.exercise_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. F4 · derivative.expiration_date: All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2025 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 16, 2023, 25% of the aggregate shares vest on March 16, 2024, and 25% of the aggregate shares vest on March 16, 2025. Vested shares will be delivered to the reporting person upon the vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 934 | $8.27 | $7,724.18 |
DisclosureSEC source: 0000805928-23-000030 · wf-form4_167936091488272.xml · nonDerivative · entry 4 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,662 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000030 · wf-form4_167936091488272.xml · nonDerivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,596 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 1,835 | $8.27 | $15,175.45 |
DisclosureSEC source: 0000805928-23-000030 · wf-form4_167936091488272.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,596 F2 · shares: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 01:08 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionCommon Stock | 5,900 | $0.00 | $0.00 |
DisclosureSEC source: 0000805928-23-000030 · wf-form4_167936091488272.xml · nonDerivative · entry 1 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 112,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: This reflects the number of restricted stock units that became vested as of March 16, 2023. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 02:34 UTC | Axogen, Inc. AXGN · Entity 4297 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $5.09 | $0.00 |
DisclosureSEC source: 0000805928-22-000133 · wf-form4_167228127578446.xml · derivative · entry 3 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires 2022-12-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2022 Filed Dec 29, 2022 02:34 UTC | Axogen, Inc. AXGN · Entity 4297 | Tax withholdingCommon Stock | 10,784 | $9.44 | $101,800.96 |
DisclosureSEC source: 0000805928-22-000133 · wf-form4_167228127578446.xml · nonDerivative · entry 2 DeVinney Erick Wayne · CIK 0001595972 · VP Peripheral Nerve Science 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,968 F1 · shares: This Form is being filed to report the exercise of a stock option for a total of 20,000 shares by means of a stock swap. A stock swap is a method of exercising a stock option in which the option holder pays the exercise price using shares of stock already owned. As a result of this stock, the Reporting Person, on a net basis, acquired ownership of an additional 9,216 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.